Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Iron_Age
|
| gptkbp:accessories |
manufactured in the USA
|
| gptkbp:administration_guidelines |
follow specific protocols for IV administration
|
| gptkbp:administration_rate |
over 15 minutes
|
| gptkbp:approves |
gptkb:2009
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Feraheme
|
| gptkbp:class |
iron supplements
|
| gptkbp:clinical_trial |
Phase 3
demonstrated efficacy in iron repletion iron deficiency anemia in patients with CKD |
| gptkbp:clinical_use |
patients with chronic kidney disease
|
| gptkbp:compatibility |
other intravenous medications
|
| gptkbp:contraindication |
known hypersensitivity to ferumoxytol
|
| gptkbp:dosage_form |
injection
|
| gptkbp:drug_interactions |
may interact with certain medications
|
| gptkbp:effective_date |
FDA approved
|
| gptkbp:formulation |
ferumoxytol in saline solution
|
| gptkbp:healthcare |
injectable solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
Feraheme
|
| gptkbp:indication |
chronic kidney disease
|
| gptkbp:ingredients |
ferumoxytol
|
| gptkbp:is_effective_against |
effective in increasing iron levels
|
| gptkbp:is_monitored_by |
monitor for hypersensitivity reactions
|
| gptkbp:label |
includes dosing information and warnings
|
| gptkbp:lifespan |
approximately 15 hours
|
| gptkbp:manufacturer |
gptkb:AMAG_Pharmaceuticals
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
gptkb:United_States
|
| gptkbp:mechanism_of_action |
iron replacement
|
| gptkbp:packaging |
single-use vials
|
| gptkbp:patient_compliance |
generally well tolerated
|
| gptkbp:patient_education |
instruct on signs of allergic reactions
|
| gptkbp:patient_population |
adults and pediatric patients over 6 years old
|
| gptkbp:pharmacokinetics |
rapid distribution
increases hemoglobin levels |
| gptkbp:previous_name |
ferumoxytol
|
| gptkbp:price |
varies by provider
|
| gptkbp:provides_guidance_on |
recommended for iron deficiency anemia in CKD patients
|
| gptkbp:regulatory_compliance |
granted by FDA after clinical trials
|
| gptkbp:research |
conducted to assess long-term safety
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:safety_features |
generally favorable with monitoring.
|
| gptkbp:safety_measures |
risk of serious allergic reactions
|
| gptkbp:service_frequency |
once or twice
|
| gptkbp:side_effect |
dizziness
headache nausea allergic reactions diarrhea hypotension |
| gptkbp:storage |
room temperature
|
| gptkbp:supply_chain |
managed by AMAG Pharmaceuticals
|
| gptkbp:used_for |
treatment of iron deficiency anemia
|
| gptkbp:bfsParent |
gptkb:AMAG_Pharmaceuticals
|
| gptkbp:bfsLayer |
8
|